Zobrazeno 1 - 10
of 23
pro vyhledávání: '"M. Biakhov"'
Autor:
George Fountzilas, W. Baronius, Peter Reichardt, D. Irwin, Guenther G. Steger, Albrecht Kretzschmar, M. Biakhov, C. Slabber, T. Südhoff, A. Garin, Meinolf Karthaus, Norbert Marschner, H. Kröning, C. Giorgetti, N.G.F. Abecasis
Publikováno v:
Annals of Oncology. 17:289-296
Background: Cancer patients receiving chemotherapy experience thromboembolic complications associated with the use of long-term indwelling central venous catheters (CVCs). This prospective, double-blind, placebo-controlled, multicenter study evaluate
Autor:
Els Vercammen, Vladimir Semiglazov, M. Pawlicki, Xiangyang Liu, Sergei Tjulandin, M. Biakhov, David Dodwell, Konstantinas Valuckas, George M. Manikhas, Anton Roth, Edouard Voznyi, José Baselga, Tadeusz Pienkowski, Antoly Makhson, Brian Leyland-Jones
Publikováno v:
Journal of Clinical Oncology. 23:5960-5972
Purpose To evaluate the effect on survival and quality of life of maintaining hemoglobin (Hb) in the range of 12 to 14 g/dL with epoetin alfa versus placebo in women with metastatic breast cancer (MBC) receiving first-line chemotherapy. Patients and
Autor:
Malcolm J. Moore, Jeffrey R. Infante, Werner Scheithauer, Sunil R. Hingorani, Xinyu Wei, E. Gabriela Chiorean, Thomas J. Ervin, Jeremy K. Hon, M. Biakhov, Daniel D. Von Hoff, Alfredo Romano, Ramesh K. Ramanathan, Colin D. Weekes, Josep Tabernero, Francis P. Arena, David Goldstein, Vinod Ganju
Publikováno v:
Journal of Clinical Oncology. 31:4059-4059
4059^ Background: In MPACT, pts who received nab-P + G vs G had improved overall survival (OS; median 8.5 vs 6.7 mo; HR 0.72; p= 0.000015). Here we assessed potential PFs of OS. Methods: 861 pts with MPC were randomized 1:1, stratified by region, pre
Autor:
Laslo Roman, M. Biakhov, Antonio Llombart, Marcel Rozencweig, Nozar Azarnia, Clifford A. Hudis, Alexey Manikhas, José Baselga, Salvatore Forenza, Lokanatha Dasappa, Javier Cortes, Ronald H. Goldfarb, Jeri Matera, Lorena de la Peña, Vladimir Semiglazov
Publikováno v:
Journal of Clinical Oncology. 31:517-517
517 Background: M in combination with T has shown promising activity and cardiac safety in MBC patients (pts). We conducted a randomized Phase III trial of first-line M plus T and P (MTP) versus T plus P (TP) in HER2+ MBC pts. Methods: Pts with HER2+
Autor:
Oleg Gladkov, Laurence Bernard, Daniel Kramer, Piotr Serwatowski, Philip B Komarnitsky, Maciej Krzakowski, Janusz Tomeczko, Rodryg Ramlau, Janusz Milanowski, M. Biakhov
Publikováno v:
Journal of Clinical Oncology. 30:7090-7090
7090 Background: huKS-IL2 immunocytokine is a humanized antibody specific for EpCAM, fused at its Fc end to two molecules of IL2. Results of a phase 1b study of huKS-IL2 plus low-dose CTX, and preclinical data, provided a rationale to evaluate this c
Autor:
L. Gianni, A. Lluch, Vladimir Semiglazov, M. Pickl, Giampaolo Bianchini, F. Vázquez-Mazón, J. Baselga, S. Tjulandin, Anton Belousov, P. Gomez Pardo, Milvia Zambetti, Astrid Koehler, M. Biakhov, Wolfgang Eiermann, Aleix Prat
Publikováno v:
Journal of Clinical Oncology. 29:554-554
554 Background: Gene expression profiling can be used to predict the likelihood of achieving a pathological complete response (pCR) to neoadjuvant chemotherapy (CT) in patients with primary breast ...
Autor:
Wolfgang Eiermann, S. Tjulandin, José Baselga, M. Pickl, F. J. Vazquez Mazon, Anton Belousov, Milvia Zambetti, L. Gianni, M. Biakhov, Giampaolo Bianchini, Aleix Prat, Astrid Koehler, A. Lluch, Vladimir Semiglazov
Publikováno v:
Journal of Clinical Oncology. 29:529-529
529 Background: HER2-positive/ER+ and HER2-positive/ER– breast cancers have different patterns of gene expression and intracellular pathway activation. We assessed the role of selected biomarkers in predicting the likelihood of achieving a patholog
Autor:
J. L. Kelley, Claudia Lebedinsky, J. Nunez, Jan B. Vermorken, Trilok V. Parekh, M. Biakhov, B. Kong
Publikováno v:
Journal of Clinical Oncology. 28:e15529-e15529
e15529 Background: OVA-301 was an open-label, multicenter, randomized phase III study comparing Tr+PLD to PLD alone in 672 patients (pts) with ROC. The combination of Tr+PLD demonstrated significan...
Publikováno v:
Journal of Clinical Oncology. 27:4026-4026
4026 Background: Picoplatin (Pico) was designed to overcome platinum resistance and has the potential for improved safety compared to other platinum agents. FOLFOX (5-FU, LV, oxaliplatin [oxali]) treatment for advanced CRC has dose-limiting oxali- re
Publikováno v:
European Journal of Cancer Supplements. 6:67